HUP0200021A2 - 4-(Heterociklikus szulfonamido)-5-metoxi-6-(2-metoxi-fenoxi)-2-fenil- vagy -piridil-pirimidinek, mint endothelin receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents
4-(Heterociklikus szulfonamido)-5-metoxi-6-(2-metoxi-fenoxi)-2-fenil- vagy -piridil-pirimidinek, mint endothelin receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0200021A2 HUP0200021A2 HU0200021A HUP0200021A HUP0200021A2 HU P0200021 A2 HUP0200021 A2 HU P0200021A2 HU 0200021 A HU0200021 A HU 0200021A HU P0200021 A HUP0200021 A HU P0200021A HU P0200021 A2 HUP0200021 A2 HU P0200021A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- hydrogen
- heterocyclylsulfonamido
- pyridylpyrimidines
- methoxyphenoxy
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 229940118365 Endothelin receptor antagonist Drugs 0.000 title 1
- 239000002308 endothelin receptor antagonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 cyano- Chemical class 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000008753 endothelial function Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000005182 hydroxyalkylcarbonyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002769 thiazolinyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 230000006442 vascular tone Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Az (I) általános képletű vegyületek[mely képletben R1 jelentésepiridil-, pirrolil-, imidazolil-, tiazolil-, tiazolinil- vagyoxazolil-csoport, amely csoportok adott esetben halogénatommal,alkil-, hidroxi-alkil- vagy alkenilcsoporttal helyettesítve lehetnek;R2 jelentése R21, -Y-R22 vagy heterociklikus csoport, amelyheterociklikus csoport adott esetben egy, két vagy három, azonos vagykülönböző hidroxil-, alkenil-, amino-, alkanoil-amino-, alkoxi-karbonil-amino-, alkil- és/vagy hidroxi- alkil-helyettesítőthordozhat; R21 jelentése ciano-, hidroxi- alkil-, karboxil-, -C(O)NRaRb, -(CH2)1-4-NHRc, -(CH2)1-4-NHC(O)NH(CH2)0-3CH3, amidino-,hidroxi-amidino-, alkoxi-karbonil- vagy hidroxi-alkoxi-karbonilcsoport; R22 jelentése hidrogénatom, alkanoil-, karboxialkil,alkoxi-karbonil-, alkoxi-karbonil- alkil-, karbamoil- alkil, di-alkil-karbamoil- alkil-, allil- alkil- vagy hidroxi- alkilcsoport; Rajelentése hidrogénatom vagy adott esetben hidroxil- vagyalkoxicsoporttal helyettesített alkilcsoport; Rb jelentésehidrogénatom vagy alkilcsoport; Rc jelentése hidrogénatom, acetil-vagy alkilszulfonilcsoport; X jelentése -CH- vagy -N- ; és Y jelentése-O- vagy -NH-] gyógyászatilag alkalmas sóik és észtereik rendellenesvaszkuláris tónussal és hibás endothel működéssel társultrendellenességek és betegségek kezelésére és/vagy megelőzésérealkalmazhatók. A találmány továbbá kiterjed a vegyletek előállításieljárására és hatóanyagként ezeket tartalmazó gyógyszerkészítményekreis. Ó
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99100784 | 1999-01-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0200021A2 true HUP0200021A2 (hu) | 2002-05-29 |
HUP0200021A3 HUP0200021A3 (en) | 2003-01-28 |
Family
ID=8237359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0200021A HUP0200021A3 (en) | 1999-01-18 | 2000-01-10 | 4-(heterocyclylsulfonamido)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists, process for their preparation and pharmaceutical compositions containing them |
Country Status (31)
Country | Link |
---|---|
US (1) | US6242601B1 (hu) |
EP (1) | EP1149091B1 (hu) |
JP (1) | JP3983477B2 (hu) |
KR (1) | KR100478797B1 (hu) |
CN (1) | CN1340049A (hu) |
AR (1) | AR029879A1 (hu) |
AT (1) | ATE389648T1 (hu) |
AU (1) | AU763112B2 (hu) |
BR (1) | BR0007595A (hu) |
CA (1) | CA2359363C (hu) |
CO (1) | CO5150187A1 (hu) |
CZ (1) | CZ20012546A3 (hu) |
DE (1) | DE60038365D1 (hu) |
ES (1) | ES2301476T3 (hu) |
GC (1) | GC0000248A (hu) |
HR (1) | HRP20010515A2 (hu) |
HU (1) | HUP0200021A3 (hu) |
IL (2) | IL144055A0 (hu) |
MA (1) | MA27124A1 (hu) |
MY (1) | MY121136A (hu) |
NO (1) | NO322800B1 (hu) |
NZ (1) | NZ512662A (hu) |
PE (1) | PE20001421A1 (hu) |
PL (1) | PL350093A1 (hu) |
RU (1) | RU2224757C2 (hu) |
TR (1) | TR200102071T2 (hu) |
TW (1) | TWI284642B (hu) |
UY (1) | UY25904A1 (hu) |
WO (1) | WO2000042035A1 (hu) |
YU (1) | YU50001A (hu) |
ZA (1) | ZA200105279B (hu) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
US7517880B2 (en) * | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
ATE556713T1 (de) * | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
ME00275B (me) * | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US6417360B1 (en) * | 1999-03-03 | 2002-07-09 | Hoffmann-La Roche Inc. | Heterocyclic sulfonamides |
MY140724A (en) | 2000-07-21 | 2010-01-15 | Actelion Pharmaceuticals Ltd | Novel arylethene-sulfonamides |
NZ525614A (en) * | 2000-12-18 | 2005-03-24 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
SI1450799T1 (sl) * | 2001-12-03 | 2007-02-28 | Bayer Pharmaceuticals Corp | Aril secninske spojine v kombinaciji z drugimi citostaticnimi ali citotoksicnimi sredstvi za zdravljenje cloveskih rakov |
ATE529406T1 (de) | 2002-02-11 | 2011-11-15 | Bayer Healthcare Llc | Aryl-harnstoffe als kinase inhibitoren |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
WO2003068223A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
AU2003209119A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
RU2329255C2 (ru) * | 2002-12-02 | 2008-07-20 | Актелион Фармасьютиклз Лтд | Пиримидинсульфамиды и их использование в качестве антагонистов эндотелиальных рецепторов |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
US7269460B2 (en) * | 2003-02-28 | 2007-09-11 | Medtronic, Inc. | Method and apparatus for evaluating and optimizing ventricular synchronization |
JP4860474B2 (ja) | 2003-05-20 | 2012-01-25 | バイエル、ファーマシューテイカルズ、コーポレイション | Pdgfrによって仲介される病気のためのジアリール尿素 |
DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
BRPI0709950A2 (pt) * | 2006-04-13 | 2011-08-02 | Actelion Pharmaceuticals Ltd | uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin |
KR20090020559A (ko) | 2006-05-29 | 2009-02-26 | 니콕스 에스. 에이. | 엔도셀린 수용체 길항제로서의 질화 헤테로시클릭 화합물 |
AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
PL3667804T3 (pl) * | 2014-11-21 | 2021-11-02 | Daikin Industries, Ltd. | Roztwór elektrolitu zawierający nienasycone cykliczne węglany, zawierające je urządzenie elektrochemiczne i litowo-jonowa bateria akumulatorowa |
CN109260164A (zh) * | 2018-10-07 | 2019-01-25 | 威海贯标信息科技有限公司 | 一种阿伏生坦片剂组合物 |
CN112778215B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | 2-甲氧基苯氧基嘧啶类抗肿瘤化合物及其制备方法和应用 |
CN112898208B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | 苯基嘧啶胺类抗肿瘤化合物及其制备方法和应用 |
WO2023111299A1 (en) | 2021-12-17 | 2023-06-22 | Idorsia Pharmaceuticals Ltd | Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2162630C (en) * | 1994-11-25 | 2007-05-01 | Volker Breu | Sulfonamides |
US5837708A (en) | 1994-11-25 | 1998-11-17 | Hoffmann-La Roche Inc. | Sulphonamides |
WO1996016963A1 (de) * | 1994-11-25 | 1996-06-06 | F. Hoffmann-La Roche Ag | Sulfonamide und deren verwendung als heilmittel |
TW313568B (hu) * | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
CN1102580C (zh) * | 1995-12-20 | 2003-03-05 | 山之内制药株式会社 | 芳基乙烯基磺酰胺衍生物及其医药组合物 |
-
2000
- 2000-01-07 TW TW089100181A patent/TWI284642B/zh not_active IP Right Cessation
- 2000-01-10 TR TR2001/02071T patent/TR200102071T2/xx unknown
- 2000-01-10 BR BR0007595-7A patent/BR0007595A/pt not_active Application Discontinuation
- 2000-01-10 CZ CZ20012546A patent/CZ20012546A3/cs unknown
- 2000-01-10 CA CA002359363A patent/CA2359363C/en not_active Expired - Fee Related
- 2000-01-10 AT AT00904889T patent/ATE389648T1/de not_active IP Right Cessation
- 2000-01-10 PL PL00350093A patent/PL350093A1/xx not_active Application Discontinuation
- 2000-01-10 IL IL14405500A patent/IL144055A0/xx not_active IP Right Cessation
- 2000-01-10 HU HU0200021A patent/HUP0200021A3/hu unknown
- 2000-01-10 DE DE60038365T patent/DE60038365D1/de not_active Expired - Lifetime
- 2000-01-10 KR KR10-2001-7008996A patent/KR100478797B1/ko not_active IP Right Cessation
- 2000-01-10 CN CN00803754A patent/CN1340049A/zh active Pending
- 2000-01-10 ES ES00904889T patent/ES2301476T3/es not_active Expired - Lifetime
- 2000-01-10 YU YU50001A patent/YU50001A/sh unknown
- 2000-01-10 EP EP00904889A patent/EP1149091B1/en not_active Expired - Lifetime
- 2000-01-10 AU AU26630/00A patent/AU763112B2/en not_active Ceased
- 2000-01-10 NZ NZ512662A patent/NZ512662A/en unknown
- 2000-01-10 JP JP2000593603A patent/JP3983477B2/ja not_active Expired - Lifetime
- 2000-01-10 RU RU2001122114/04A patent/RU2224757C2/ru not_active IP Right Cessation
- 2000-01-10 WO PCT/EP2000/000103 patent/WO2000042035A1/en active IP Right Grant
- 2000-01-13 PE PE2000000025A patent/PE20001421A1/es not_active Application Discontinuation
- 2000-01-13 US US09/482,810 patent/US6242601B1/en not_active Expired - Fee Related
- 2000-01-14 AR ARP000100159A patent/AR029879A1/es unknown
- 2000-01-14 CO CO00001821A patent/CO5150187A1/es unknown
- 2000-01-14 MY MYPI20000124A patent/MY121136A/en unknown
- 2000-01-14 UY UY25904A patent/UY25904A1/es unknown
- 2000-01-17 GC GCP2000481 patent/GC0000248A/en active
-
2001
- 2001-06-26 ZA ZA200105279A patent/ZA200105279B/en unknown
- 2001-06-28 IL IL144055A patent/IL144055A/en unknown
- 2001-07-10 HR HR20010515A patent/HRP20010515A2/hr not_active Application Discontinuation
- 2001-07-12 NO NO20013454A patent/NO322800B1/no unknown
- 2001-07-17 MA MA26270A patent/MA27124A1/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0200021A2 (hu) | 4-(Heterociklikus szulfonamido)-5-metoxi-6-(2-metoxi-fenoxi)-2-fenil- vagy -piridil-pirimidinek, mint endothelin receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0203136A2 (hu) | Piperazinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
ATE212991T1 (de) | Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften | |
IL142649A0 (en) | Azole derivatives | |
HUP0102471A2 (hu) | 4-Benzil-piperidin alkilszulfoxid heterociklusok és használatuk altípus-szelektív NMDA antagonistaként és ezeket tartalmazó gyógyszerkészítmények | |
AU4437896A (en) | Piperidine derivatives having tachykinin antagonist activity | |
AU2458392A (en) | Novel medical use for tachykinin antagonists | |
HUP0400851A2 (hu) | Dihidro-benzo[b][1,4]diazepin-2-on-származékok, mint MGluR2 II antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0102101A2 (hu) | Protein-tirozin-kináz inhibitor benzotiazolszármazékok és az ezeket tartalmazó gyógyszerkészítmények | |
HUP9900949A2 (hu) | Triazolilcsoportot tartalmazó foszfátok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
MY117557A (en) | 1-(1,2-disubstituted piperidinyl)-4- substituted piperidine derivatives | |
WO2003035668A3 (en) | Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha | |
MX9805181A (es) | Derivados de lactona a partir de derivados de 17.beta- carboxi, carbotio y amida androstano. | |
AU3563695A (en) | Novel piperidine derivatives with paf antagonist activity | |
MY129224A (en) | 4-phenyl-pyridine derivatives | |
IL142893A0 (en) | Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same | |
HUP0203585A2 (hu) | Gyógyszerkombinációk | |
MY132062A (en) | Apolipoprotein-b synthesis inhibitors | |
GB9502644D0 (en) | Heterocyclic derivatives | |
HUP0201315A2 (hu) | 4-Fenil-pirimidin-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények | |
ATE342261T1 (de) | Pyranderivate als inhibitoren von ace und nep | |
RS50109B (sr) | Derivati 4-heterociklilsulfonamidil-6-metoksi-5-(2-metoksi- fenoksi)-2-piridil-piridimina, njihovo dobivanje i primena kao antagonisti endotelinskih receptora | |
KR970705555A (ko) | 브라디키닌 길항근으로서 디하이드로피리딘 유도체(dihydropyridine derivatives as bradykinin antagonists) | |
FR2778404B1 (fr) | Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant | |
DE69712325T2 (de) | Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |